130 related articles for article (PubMed ID: 36971493)
1. Chemical Exchange Saturation Transfer MRI: Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non-Small Cell Lung Cancer Patients.
Ohno Y; Yui M; Yamamoto K; Takenaka D; Koyama H; Nagata H; Ueda T; Ikeda H; Ozawa Y; Toyama H; Yoshikawa T
J Magn Reson Imaging; 2023 Jul; 58(1):174-186. PubMed ID: 36971493
[TBL] [Abstract][Full Text] [Related]
2. Amide proton transfer-weighted imaging to differentiate malignant from benign pulmonary lesions: Comparison with diffusion-weighted imaging and FDG-PET/CT.
Ohno Y; Kishida Y; Seki S; Yui M; Miyazaki M; Koyama H; Yoshikawa T
J Magn Reson Imaging; 2018 Apr; 47(4):1013-1021. PubMed ID: 28799280
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
[TBL] [Abstract][Full Text] [Related]
4. Computed DWI MRI Results in Superior Capability for N-Stage Assessment of Non-Small Cell Lung Cancer Than That of Actual DWI, STIR Imaging, and FDG-PET/CT.
Ohno Y; Yui M; Takenaka D; Yoshikawa T; Koyama H; Kassai Y; Yamamoto K; Oshima Y; Hamabuchi N; Hanamatsu S; Obama Y; Ueda T; Ikeda H; Hattori H; Murayama K; Toyama H
J Magn Reson Imaging; 2023 Jan; 57(1):259-272. PubMed ID: 35753082
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Amide Proton Transfer-Weighted Imaging for Lung Cancer Subtype and Epidermal Growth Factor Receptor: A Comparative Study With Diffusion and Metabolic Parameters.
Meng N; Fu F; Feng P; Li Z; Gao H; Wu Y; Zhang J; Wei W; Yuan J; Yang Y; Liu H; Cheng J; Wang M
J Magn Reson Imaging; 2022 Oct; 56(4):1118-1129. PubMed ID: 35258145
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
7. Amide proton transfer (APT) and magnetization transfer (MT) in predicting short-term therapeutic outcome in nasopharyngeal carcinoma after chemoradiotherapy: a feasibility study of three-dimensional chemical exchange saturation transfer (CEST) MRI.
Liu W; Wang X; Xie S; Liu WV; Masokano IB; Bai Y; Chen J; Zhong L; Luo Y; Zhou G; Li W; Pei Y
Cancer Imaging; 2023 Sep; 23(1):80. PubMed ID: 37658446
[TBL] [Abstract][Full Text] [Related]
8. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
9. Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer patients.
Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Kassai Y; Yui M; Matsumoto S; Sugimura K
Eur J Radiol; 2015 Nov; 84(11):2321-31. PubMed ID: 26231045
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Contrast-enhanced Area-detector CT vs Dynamic Contrast-enhanced Perfusion MRI vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy.
Seki S; Fujisawa Y; Yui M; Kishida Y; Koyama H; Ohyu S; Sugihara N; Yoshikawa T; Ohno Y
Magn Reson Med Sci; 2020 Feb; 19(1):29-39. PubMed ID: 30880291
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced perfusion area-detector CT assessed with various mathematical models: Its capability for therapeutic outcome prediction for non-small cell lung cancer patients with chemoradiotherapy as compared with that of FDG-PET/CT.
Ohno Y; Fujisawa Y; Koyama H; Kishida Y; Seki S; Sugihara N; Yoshikawa T
Eur J Radiol; 2017 Jan; 86():83-91. PubMed ID: 28027771
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
13. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
[TBL] [Abstract][Full Text] [Related]
14. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
[TBL] [Abstract][Full Text] [Related]
15. The lung cancers: staging and response, CT,
Owens C; Hindocha S; Lee R; Millard T; Sharma B
Br J Radiol; 2023 Aug; 96(1148):20220339. PubMed ID: 37097296
[TBL] [Abstract][Full Text] [Related]
16. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
[TBL] [Abstract][Full Text] [Related]
17. Amide Proton Transfer-Weighted Imaging and Multiple Models Intravoxel Incoherent Motion-Based
Meng N; Jiang H; Sun J; Shen L; Wang X; Zhou Y; Wu Y; Fu F; Yuan J; Yang Y; Wang Z; Wang M
J Magn Reson Imaging; 2023 Oct; ():. PubMed ID: 37850873
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
[TBL] [Abstract][Full Text] [Related]
19. Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy.
Adusumilli P; Elsayed N; Theophanous S; Samuel R; Cooper R; Casanova N; Tolan DJ; Gilbert A; Scarsbrook AF
Eur Radiol; 2022 Aug; 32(8):5086-5096. PubMed ID: 35274187
[TBL] [Abstract][Full Text] [Related]
20. A Comparative Study of Amide Proton Transfer Weighted Imaging and Intravoxel Incoherent Motion MRI Techniques Versus (18) F-FDG PET to Distinguish Solitary Pulmonary Lesions and Their Subtypes.
Fang T; Meng N; Feng P; Huang Z; Li Z; Fu F; Yuan J; Yang Y; Liu H; Roberts N; Wang M
J Magn Reson Imaging; 2022 May; 55(5):1376-1390. PubMed ID: 34723413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
